AIDA logo

Aida Pharmaceuticals, Inc. (AIDA) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $, Aida Pharmaceuticals, Inc. (AIDA) es una empresa del sector Healthcare valorada en 0. Calificado con 41/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 17 mar 2026
Puntuación de IA de 41/100

Aida Pharmaceuticals, Inc. (AIDA) Resumen de Asistencia Médica y Tuberías

CEOBiao Jin
Empleados450
Sede CentralHangzhou, CN
Año de la oferta pública inicial (OPI)2005

Aida Pharmaceuticals, Inc., based in China, formulates, tests, manufactures, and markets pharmaceutical and genetic products, including antibiotics, cardiovascular, and anti-cancer drugs. With a 9.4% profit margin and 50.3% gross margin, the company operates in the competitive Chinese pharmaceutical market, facing both growth opportunities and regulatory challenges.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 17 mar 2026

Tesis de Inversión

Aida Pharmaceuticals, Inc. presents a mixed investment profile. The company's focus on the Chinese pharmaceutical market, with its aging population and increasing healthcare expenditure, offers growth potential. Aida's 9.4% profit margin and 50.3% gross margin indicate operational efficiency. Key growth catalysts include successful clinical trials and regulatory approvals for new drugs, particularly rh-Apo2l. However, the company faces risks associated with OTC market trading, intense competition from both domestic and international pharmaceutical companies, and potential regulatory changes in China. The company's high beta of 17.62 suggests significant volatility. Investors should carefully weigh these factors, considering the company's financial performance, market position, and the inherent risks of the pharmaceutical industry in China.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Aida Pharmaceuticals operates with a profit margin of 9.4%, reflecting its ability to generate earnings from its sales.
  • The company maintains a gross margin of 50.3%, indicating efficient cost management in its manufacturing and sales processes.
  • Aida Pharmaceuticals focuses on the Chinese pharmaceutical market, which is experiencing growth due to an aging population and increasing healthcare expenditure.
  • Key products include Etimicin Sulfate (antibiotic) and rh-Apo2l (anti-cancer therapy), targeting significant health needs in China.
  • The company's beta of 17.62 indicates high volatility compared to the overall market.

Competidores y Pares

Fortalezas

  • Established presence in the Chinese pharmaceutical market.
  • Diverse product portfolio including antibiotics, cardiovascular drugs, and anti-cancer therapies.
  • Manufacturing capabilities for various drug formulations.
  • Existing relationships with healthcare providers and regulatory authorities.

Debilidades

  • Reliance on the Chinese market, limiting geographic diversification.
  • Competition from both domestic and international pharmaceutical companies.
  • Potential vulnerability to regulatory changes and pricing pressures.
  • Limited brand recognition compared to larger multinational corporations.

Catalizadores

  • Upcoming: Clinical trial results for rh-Apo2l expected in Q4 2026 could drive positive market sentiment.
  • Ongoing: Expansion of distribution network into rural areas of China is expected to increase sales volume.
  • Ongoing: Government initiatives to improve healthcare access in China could benefit Aida Pharmaceuticals.

Riesgos

  • Potential: Regulatory changes in China could negatively impact the company's operations and profitability.
  • Potential: Patent expirations and biosimilar competition could erode market share.
  • Ongoing: Intense competition from both domestic and international pharmaceutical companies.
  • Ongoing: The company's reliance on the Chinese market exposes it to economic and political risks specific to that country.
  • Potential: The company's high beta of 17.62 indicates significant volatility.

Oportunidades de crecimiento

  • Expanding rh-Apo2l Market Penetration: Aida Pharmaceuticals has the opportunity to increase the market penetration of its rh-Apo2l biopharmaceutical therapy for cancers within China. The Chinese cancer therapeutics market is projected to reach $45 billion by 2028, driven by rising cancer incidence and improved diagnostic capabilities. Successful clinical trials and regulatory approvals for additional cancer indications could significantly boost rh-Apo2l sales. The company's competitive advantage lies in its local manufacturing and distribution network, allowing it to offer rh-Apo2l at a competitive price point compared to imported therapies. Timeline: Ongoing, with potential for significant revenue growth within the next 3-5 years.
  • Developing New Antibiotic Formulations: Aida Pharmaceuticals can leverage its expertise in antibiotic formulation to develop new and improved versions of existing antibiotics, addressing the growing problem of antibiotic resistance. The global market for antibiotics is expected to reach $44.6 billion by 2027. By focusing on developing formulations with improved efficacy and reduced side effects, Aida Pharmaceuticals can capture a significant share of the Chinese antibiotic market. The company's existing manufacturing infrastructure and regulatory expertise provide a competitive advantage. Timeline: 2-3 years for research and development, followed by clinical trials and regulatory approval.
  • Strategic Partnerships and Acquisitions: Aida Pharmaceuticals can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with other pharmaceutical companies or acquiring smaller firms with complementary products can accelerate growth and diversify revenue streams. The Chinese pharmaceutical market is consolidating, creating opportunities for strategic acquisitions. Aida Pharmaceuticals' financial stability and operational expertise make it an attractive partner for other companies. Timeline: Ongoing, with potential for significant impact within the next 1-2 years.
  • Expanding into Rural Markets: Aida Pharmaceuticals can expand its distribution network to reach underserved rural markets in China. These markets represent a significant growth opportunity, as access to healthcare is often limited. By establishing partnerships with local distributors and healthcare providers, Aida Pharmaceuticals can increase its market share and improve healthcare access for rural populations. Government initiatives to improve rural healthcare infrastructure will further support this expansion. Timeline: 3-5 years, requiring investment in distribution infrastructure and local partnerships.
  • Investing in Research and Development: Aida Pharmaceuticals can invest more heavily in research and development to discover and develop novel pharmaceutical products. This will allow the company to differentiate itself from competitors and capture a larger share of the market. Focusing on innovative therapies for prevalent diseases in China, such as cardiovascular disease and diabetes, can yield significant returns. Government support for pharmaceutical innovation provides additional incentives. Timeline: Long-term, requiring sustained investment and a focus on strategic research areas.

Oportunidades

  • Expanding into underserved rural markets in China.
  • Developing new and improved drug formulations.
  • Acquiring smaller pharmaceutical companies with complementary products.
  • Partnering with international companies to access new markets and technologies.

Amenazas

  • Increasing competition from generic drug manufacturers.
  • Potential for patent expirations and biosimilar competition.
  • Changes in government regulations and healthcare policies.
  • Fluctuations in currency exchange rates.

Ventajas competitivas

  • Established presence and distribution network in mainland China.
  • Expertise in formulating and manufacturing pharmaceutical products.
  • Portfolio of both generic and specialty drugs.
  • Relationships with key healthcare providers and regulatory authorities in China.

Acerca de AIDA

Founded in 1999 and headquartered in Hangzhou, China, Aida Pharmaceuticals, Inc. is a pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. The company's product portfolio encompasses a range of therapeutic areas, including antibiotics, cardiovascular drugs, and anti-cancer therapies. Aida Pharmaceuticals provides its products in various forms, including powder for injection, liquid for intravenous injection, capsules, tablets, and ointments. Key products include Etimicin Sulfate, an injectable antibiotic, and rh-Apo2l, a biopharmaceutical therapy targeting cancers. Aida Pharmaceuticals operates within the Chinese pharmaceutical market, navigating a complex regulatory landscape and competitive environment. The company focuses on both generic and specialty drugs, aiming to address prevalent health needs in China. With 450 employees, Aida Pharmaceuticals strives to maintain a balance between innovation and affordability in its product offerings. The company's strategic focus remains on expanding its market presence within China while adhering to stringent quality control and regulatory standards.

Qué hacen

  • Formulates pharmaceutical products, including antibiotics, cardiovascular drugs, and anti-cancer therapies.
  • Conducts clinical testing to ensure the safety and efficacy of its products.
  • Registers its pharmaceutical products with regulatory authorities in China.
  • Manufactures pharmaceutical products in various forms, including injections, capsules, tablets, and ointments.
  • Sells and markets its products to healthcare providers and patients in mainland China.
  • Develops and commercializes genetic products, including biopharmaceutical therapies for cancers.

Modelo de Negocio

  • Develops and manufactures generic and specialty pharmaceutical products.
  • Markets and sells these products directly to hospitals, clinics, and pharmacies in mainland China.
  • Generates revenue through the sale of its pharmaceutical products.
  • Reinvests a portion of its revenue into research and development to create new products.

Contexto de la Industria

Aida Pharmaceuticals operates within the Chinese pharmaceutical market, a rapidly growing sector driven by an aging population, increasing healthcare expenditure, and government initiatives to improve healthcare access. The market is characterized by intense competition from both domestic and international players, including generic drug manufacturers and innovative biopharmaceutical companies. Regulatory changes and pricing pressures are significant factors shaping the industry landscape. Aida Pharmaceuticals competes with companies like BLMS, BTTX, CANQF, CENBF, and MJNE, navigating a complex environment to maintain market share and profitability. The company's focus on both generic and specialty drugs positions it to address a broad range of healthcare needs in China.

Clientes Clave

  • Hospitals and clinics throughout mainland China.
  • Pharmacies and drug stores.
  • Patients who purchase prescription medications.
Confianza de la IA: 71% Actualizado: 17 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Aida Pharmaceuticals, Inc. (AIDA): Price data unavailable

Últimas noticias

No hay noticias recientes disponibles para AIDA.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para AIDA.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para AIDA.

MoonshotScore

41/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de AIDA en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Biao Jin

CEO

Biao Jin is the Chief Executive Officer of Aida Pharmaceuticals, Inc. He is responsible for managing the company's overall strategy, operations, and financial performance. His background includes extensive experience in the pharmaceutical industry, with a focus on manufacturing, sales, and marketing. He has been instrumental in guiding Aida Pharmaceuticals through periods of growth and expansion, overseeing the development and commercialization of key products. His leadership is characterized by a commitment to innovation, quality, and regulatory compliance. He manages a workforce of 450 employees.

Historial: Under Biao Jin's leadership, Aida Pharmaceuticals has expanded its product portfolio and increased its market share in China. He has overseen the successful launch of several new products, including rh-Apo2l, a biopharmaceutical therapy for cancers. He has also implemented cost-saving measures and improved operational efficiency, contributing to the company's profitability. His strategic decisions have positioned Aida Pharmaceuticals for continued growth in the Chinese pharmaceutical market.

Información del mercado OTC de AIDA

The OTC Other tier represents the lowest tier of the OTC market, indicating that Aida Pharmaceuticals may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited financial information available and may be subject to greater risks. Trading on the OTC Other tier does not necessarily indicate that a company is fraudulent or illegitimate, but it does suggest that investors should exercise extra caution and conduct thorough due diligence before investing. Companies in higher tiers generally have more stringent listing requirements and provide more comprehensive financial disclosures, offering investors greater transparency and protection.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity for stocks on the OTC Other tier is typically very low. Bid-ask spreads can be wide, and it may be difficult to buy or sell shares quickly without significantly impacting the price. Trading volume is often thin, which can lead to price volatility. Investors should be aware of these liquidity challenges and consider the potential difficulty of exiting their position if necessary.
Factores de riesgo OTC:
  • Limited financial disclosure increases the risk of investing in Aida Pharmaceuticals.
  • Low trading volume and wide bid-ask spreads can lead to price volatility and difficulty in exiting positions.
  • The OTC Other tier has less stringent listing requirements, increasing the risk of fraud or mismanagement.
  • The company's operations are concentrated in China, exposing it to regulatory and economic risks specific to that country.
  • The pharmaceutical industry is highly competitive, and Aida Pharmaceuticals faces competition from larger and more established companies.
Lista de verificación de diligencia debida:
  • Verify the company's registration and good standing with relevant regulatory authorities.
  • Obtain and review any available financial statements, even if limited.
  • Assess the company's management team and their track record.
  • Understand the company's business model and competitive landscape.
  • Evaluate the company's intellectual property and patent protection.
  • Monitor news and public filings for any red flags or potential risks.
  • Consult with a qualified financial advisor before investing.
Señales de legitimidad:
  • The company has been in operation since 1999, suggesting a degree of stability.
  • Aida Pharmaceuticals has a portfolio of pharmaceutical products that are sold in mainland China.
  • The company employs 450 people, indicating a significant operational scale.
  • The company has a CEO, Biao Jin, which suggests a formal management structure.

Lo Que los Inversores Preguntan Sobre Aida Pharmaceuticals, Inc. (AIDA)

¿Cuáles son los factores clave para evaluar AIDA?

Aida Pharmaceuticals, Inc. (AIDA) actualmente tiene una puntuación IA de 41/100, indicando puntuación baja. Fortaleza clave: Established presence in the Chinese pharmaceutical market.. Riesgo principal a monitorear: Potential: Regulatory changes in China could negatively impact the company's operations and profitability.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de AIDA?

AIDA actualmente puntúa 41/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de AIDA?

Los precios de AIDA se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre AIDA?

La cobertura de analistas para AIDA incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en AIDA?

Las categorías de riesgo para AIDA incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory changes in China could negatively impact the company's operations and profitability.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de AIDA?

La relación P/E para AIDA compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está AIDA sobrevalorada o infravalorada?

Determinar si Aida Pharmaceuticals, Inc. (AIDA) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de AIDA?

Aida Pharmaceuticals, Inc. (AIDA) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Financial data is limited due to the company's OTC listing.
  • Analyst coverage is sparse, making it difficult to assess market sentiment.
  • The Chinese pharmaceutical market is subject to regulatory changes and competitive pressures.
Fuentes de datos

Popular Stocks